SHCSotera Health Company
What is the market doing?
No clear lean: rangebound and insiders net selling (often routine).
Choppy, but holding above its 200-day average. Price is +7% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 9, 2026; selling is often routine (taxes, diversification).
Moderately shorted, settled Sep 30, 2026, about a week of normal trading to cover. Up 20% since the previous count, down from 5.6% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How SHC is trading
Sotera Health Company is +16% over the past year while the S&P 500 is +18%: 2.8 points behind the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +6.5%
vs 200-day average · close to trend
- RSI (14)
- 39
RSI (14) · neutral
- Below its 52-week high
- 7.8%
Below its 52-week high
Details›
- Last close2026-10-09
- $18.06
- 1 monthS&P 500 +2.7%
- −1.2%
- 1 yearS&P 500 +18%
- +16%
- 5 yearsS&P 500 +88%
- −26%
- vs 50-day average$18.63
- −3.1%
- 52-week high
- $19.58
- 52-week low
- $13.13
- Annualised volatility
- 38%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-09
- −$797M
| Year | Return |
|---|---|
| 2026 (year to date) | +2.4% |
| 2025 | +29% |
| 2024 | −19% |
| 2023 | +102% |
| 2022 | −65% |
| 2021 | −14% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +14% |
| Feb | 6 | 3 of 6 | −3.1% |
| Mar | 6 | 1 of 6 | −6.1% |
| Apr | 6 | 2 of 6 | −1.4% |
| May | 6 | 3 of 6 | −1.9% |
| Jun | 6 | 4 of 6 | +5.4% |
| Jul | 6 | 4 of 6 | +3.4% |
| Aug | 6 | 4 of 6 | +6.1% |
| Sep | 6 | 2 of 6 | −9.7% |
| Oct | 6 | 2 of 6 | −3.8% |
| Nov | 5 | 3 of 5 | +0.96% |
| Dec | 6 | 5 of 6 | +6.6% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Diagnostics & Research
Ranks #4 of 21 by RyuScore